As such, AAV8 is more suitable for gene delivery strategies aimed at correcting Leydig cell dysfunction or steroidogenic defects—such as those found in Lhcgr mutation-related DSD or male hypogonadism—rather than for interventions targeting the germline itself (Watanabe et al., 2018). This evidence concerns the gene LHCGR and disorder of sexual differentiation.